Pellegrino Musto
Full Professor of Hematology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
The therapeutic landscape for multiple myeloma has gradually expanded in recent decades, leading to unprecedented deep and sustained responses as well as remarkable improvements in patient survival. Nonetheless, changes in treatment algorithms have raised new demands for patients with relapsed/refractory disease, as prior exposure and refractoriness to prior therapies impact the choice of subsequent treatments. In particular, refractoriness to lenalidomide—an established backbone of treatment in both front-line and maintenance settings and a key component of many approved regimens used in relapsed disease—is associated with suboptimal clinical outcomes. Therefore, identifying the most appropriate management in lenalidomide-refractory patients, and even more so in patients who are refractory to more than one agent, is critical. At present, treatment options for this growing subgroup of patients are still limited; however, recent data from clinical research are promising. Herein, we summarized the currently available treatment options and discuss future directions based on the latest results from ongoing clinical trials.
Year:
2025
Year:
2025
Year:
2025
Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1–3 prior treatments. Methods: Our real-world, AENEID study aimed to evaluate the efficacy and safety of IsaKd in patients who relapsed after frontline lenalidomide treatment, poorly represented in the IKEMA trial. Specifically, in the present multicenter analysis, we enrolled eighty-two patients who received, between April 2022 and September 2024 and outside of clinical trials, at least one cycle of IsaKd as a second-line treatment at the first relapse after induction therapy, autologous stem cell transplantation (ASCT), and lenalidomide maintenance. Results: After a median follow-up time of 12.9 months (range, 1–77), the overall response rate, at least a very good partial response rate, and median progression-free survival time were 79.3%, 56.1%, and 24.4 months, respectively. This slightly lower performance compared to that in the IKEMA study may be attributed to the well-known poor prognostic impact of lenalidomide refractoriness (len-R), developed by all our patients during maintenance therapy, and to a higher proportion of patients with extramedullary disease present in our series, which was identified as the only factor significantly affecting the PFS in multivariable analysis. The median overall survival was not reached, as in the pivotal trial, while the 1-year survival probability was 85.1%. Regarding the safety profile, our findings were consistent with those of the IKEMA trial, with no new safety signals reported. Conclusions: These real-world data support the use of IsaKd as a valuable option for len-R MM patients relapsing after the first-line therapy, including ASCT and lenalidomide maintenance.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (30)
Cristina Santoro
Sapienza University of Rome
Maria Teresa Petrucci
-
Monica Bocchia
University of Siena
Francesca Gay
Associate Professor
University of Turin
Davide Fiore Bavaro
IRCCS Humanitas Research Hospital
Mario Delia
University of Bari Aldo Moro
Valerio De Stefano
Full Professor of Hematology
Università Cattolica del Sacro Cuore
Roman Hajek
University of Ostrava
Renato Zambello
Professore associato
University of Padova
Paolo Corradini
Full Professor of Hematology
University of Milan
Francesca Palandri
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Loreto Gesualdo
-
Tiziana Annese
Professore Associato
Università LUM Giuseppe Degennaro
Mauro Krampera
Docenti di ruolo di Ia fascia
University of Verona
MICHELE CAVO
University of Bologna
Fabrizio Pane
Università degli Studi di Napoli Federico II
Luca Arcaini
Director of Division of Hematology
Fondazione IRCCS Policlinico San Matteo
Giuseppe Alberto Maria PALUMBO
Associate Professor of Hematology
Università degli Studi di Napoli Federico II
Giuseppe Avvisati
Full Professor of Hematolgy
Università Campus Bio-Medico di Roma
Antonio d’Amati
-
Francesco Di Gennaro
Prof
University of Bari Aldo Moro
Giuseppe Ingravallo
Prof
University of Bari Aldo Moro
Donato Mannina
Head of Hematology Division
Azienda Ospedale Università Padova
Patrizia Chiusolo
Università Cattolica del Sacro Cuore
Francesco Albano
University of Bari Aldo Moro
Domenico Ribatti
-
Alfredo Di Leo
University of Bari
Roberto TAMMA
Professore Associato BIO/16
University of Bari Aldo Moro
Yasuhito Nannya
Professor
Kyoto University
ANNALISA CHIAPPELLA
Fondazione IRCCS Istituto Nazionale dei Tumori
Make your next move.
Prepare your application
Review drafts before you send them.